If you google "Colin Masters - at the ADPD Congress in Florence" should get it.
It is an interview, not his talk. One interesting point was he spoke of the LLY Sola trial as a success, with strongest results towards the end, saying with a longer trial results may have been much better.
That brings focus back to Amyloid, the primary endpoint of Prana's IMAGINE trial, and one of the levels at which PBT2 goes after Alzheimer's.
Lilly is looking for a partner for it's Sola. It takes over two years to get any results with Sola, but PBT2 gives results already in 3 months but combination of them could be what Lilly is looking for. At least Masters tells that there is some value in Sola. Could be that there is some talks between Prana and Lilly (??).
Along the lines of the 2nd class of drugs that Colin Masters felt had a shot at making their way to market, there was a new research collaboration announced today by GE Healthcare on one of those Base Inhibitor candidates:
GE Healthcare and Eisai Inc. to Partner on Alzheimer’s Disease Research
Eisai Initiates Phase I Trial of BACE Inhibitor Utilizing GE’s [18F]Flutemetamol